BACKGROUND: Human papillomavirus (HPV) infection has contributed to an increased incidence of squamous cell carcinoma of the head and neck (SCCHN). Fatigue is a major side effect of SCCHN and its treatment. However, to the authors' knowledge, the association between HPV and fatigue has not been examined to date, nor is it known whether HPV influences biological mechanisms of fatigue, including inflammation. METHODS: Patients with SCCHN who were without distant metastasis were assessed at baseline (pre-radiotherapy) and 1 month and 3 months postradiotherapy. Fatigue was measured using the Multidimensional Fatigue Inventory. Peripheral inflammation was assessed by plasma C-reactive protein (CRP), interleukin 1 receptor antagonist (IL-1ra), soluble tumor necrosis factor receptor 2 (sTNFR2), and IL-6. Mixed effect models were used to examine associations. RESULTS: A total of 94 patients who were newly diagnosed were enrolled; 53% had HPV-related tumors. Patients with HPV-unrelated tumors had higher fatigue and higher plasma CRP, sTNFR2, and IL-6 over time, especially at baseline and 3 months after intensity-modulated radiotherapy compared with those with HPV-related tumors (all P < .05). However, fatigue and plasma sTNFR2 increased more significantly from baseline to 1 month after radiotherapy in the HPV-related group compared with the HPV-unrelated group (both P < .01). Controlling for significant covariates, HPV status and inflammation were found to be independent predictors of fatigue over time. CONCLUSIONS: HPV status is an important marker of vulnerability to the behavioral and immune consequences of SCCHN and its treatment, providing support for different symptom management strategies. Special emphasis should be placed on addressing marked persistent fatigue in patients with HPV-unrelated tumors, whereas attention should be paid to the large increases in fatigue during treatment among patients with HPV-related tumors. Cancer 2018.
BACKGROUND: Human papillomavirus (HPV) infection has contributed to an increased incidence of squamous cell carcinoma of the head and neck (SCCHN). Fatigue is a major side effect of SCCHN and its treatment. However, to the authors' knowledge, the association between HPV and fatigue has not been examined to date, nor is it known whether HPV influences biological mechanisms of fatigue, including inflammation. METHODS:Patients with SCCHN who were without distant metastasis were assessed at baseline (pre-radiotherapy) and 1 month and 3 months postradiotherapy. Fatigue was measured using the Multidimensional Fatigue Inventory. Peripheral inflammation was assessed by plasma C-reactive protein (CRP), interleukin 1 receptor antagonist (IL-1ra), soluble tumornecrosis factor receptor 2 (sTNFR2), and IL-6. Mixed effect models were used to examine associations. RESULTS: A total of 94 patients who were newly diagnosed were enrolled; 53% had HPV-related tumors. Patients with HPV-unrelated tumors had higher fatigue and higher plasma CRP, sTNFR2, and IL-6 over time, especially at baseline and 3 months after intensity-modulated radiotherapy compared with those with HPV-related tumors (all P < .05). However, fatigue and plasma sTNFR2 increased more significantly from baseline to 1 month after radiotherapy in the HPV-related group compared with the HPV-unrelated group (both P < .01). Controlling for significant covariates, HPV status and inflammation were found to be independent predictors of fatigue over time. CONCLUSIONS:HPV status is an important marker of vulnerability to the behavioral and immune consequences of SCCHN and its treatment, providing support for different symptom management strategies. Special emphasis should be placed on addressing marked persistent fatigue in patients with HPV-unrelated tumors, whereas attention should be paid to the large increases in fatigue during treatment among patients with HPV-related tumors. Cancer 2018.
Authors: Canhua Xiao; Jonathan J Beitler; Kristin A Higgins; Karen Conneely; Bhakti Dwivedi; Jennifer Felger; Evanthia C Wommack; Dong M Shin; Nabil F Saba; Luke Yeeloo Ong; Jeanne Kowalski; Deborah W Bruner; Andrew H Miller Journal: Brain Behav Immun Date: 2015-10-30 Impact factor: 7.217
Authors: Julienne E Bower; Patricia A Ganz; Michael R Irwin; Lorna Kwan; Elizabeth C Breen; Steve W Cole Journal: J Clin Oncol Date: 2011-08-08 Impact factor: 44.544
Authors: Hee Chul Park; Nora A Janjan; Tito R Mendoza; Edward H Lin; Saroj Vadhan-Raj; Mandeep Hundal; Yiqun Zhang; Marc E Delclos; Christopher H Crane; Prajnan Das; Xin Shelley Wang; Charles S Cleeland; Sunil Krishnan Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-21 Impact factor: 7.038
Authors: Sarah L Gulliford; Aisha B Miah; Sinead Brennan; Dualta McQuaid; Catharine H Clark; Mike Partridge; Kevin J Harrington; James P Morden; Emma Hall; Christopher M Nutting Journal: Radiother Oncol Date: 2012-08-08 Impact factor: 6.280
Authors: Jolie Ringash; Richard Fisher; Lester Peters; Andy Trotti; Brian O'Sullivan; June Corry; Lizbeth Kenny; Sandra Nuyts; Chris Wratten; Danny Rischin Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-23 Impact factor: 7.038
Authors: Canhua Xiao; Jonathan J Beitler; Kristin A Higgins; Evanthia C Wommack; Nabil F Saba; Dong M Shin; Deborah W Bruner; Andrew H Miller; Steve Cole Journal: Brain Behav Immun Date: 2018-09-11 Impact factor: 7.217
Authors: Puja Aggarwal; Katherine A Hutcheson; Ryan P Goepfert; Adam S Garden; Naveen Garg; Frank E Mott; Clifton D Fuller; Stephen Y Lai; Gary Brandon Gunn; Mark S Chambers; Ehab Y Hanna; Erich M Sturgis; Sanjay Shete Journal: Head Neck Date: 2022-01-27 Impact factor: 3.147
Authors: Asha Mathew; Amit Jiwan Tirkey; Hongjin Li; Alana Steffen; Mark B Lockwood; Crystal L Patil; Ardith Z Doorenbos Journal: Semin Oncol Nurs Date: 2021-09-03 Impact factor: 3.527
Authors: Canhua Xiao; Ronald C Eldridge; Jonathan J Beitler; Kristin A Higgins; Cynthia E Chico; Jennifer C Felger; Evanthia C Wommack; Tish Knobf; Nabil F Saba; Dong M Shin; Deborah W Bruner; Andrew H Miller Journal: Psychosom Med Date: 2020-06 Impact factor: 4.312
Authors: Canhua Xiao; Andrew H Miller; Gang Peng; Morgan E Levine; Karen N Conneely; Hongyu Zhao; Ronald C Eldridge; Evanthia C Wommack; Sangchoon Jeon; Kristin A Higgins; Dong M Shin; Nabil F Saba; Alicia K Smith; Barbara Burtness; Henry S Park; Melinda L Irwin; Leah M Ferrucci; Bryan Ulrich; David C Qian; Jonathan J Beitler; Deborah W Bruner Journal: Int J Radiat Oncol Biol Phys Date: 2021-04-18 Impact factor: 8.013